Fierce Pharma

OCTOBER 22, 2023

Lennon and McCartney. Simon and Garfunkel. Richards and Jagger. Padcev and Keytruda? Can the cancer-fighting duo rock on in bladder cancer? | The results are in for a phase 3 bladder cancer trial assessing the combination of Seagen and Astellas' Padcev, plus Merck's Keytruda, versus standard of care chemotherapy. The figures indicate that the combo can be transformative in the indication.

Trials 119

Trials 119

JAMA Internal Medicine

OCTOBER 22, 2023

This observational cohort study assesses the occurrence of post–COVID-19 condition symptoms in Medicare enrollees prescribed nirmatrelvir and molnupiravir.

111

111

pharmaphorum

OCTOBER 22, 2023

ESMO: Roche’s Alecensa claims a first in ALK-positive NSCLC Phil.

105

105

Fierce Pharma

OCTOBER 22, 2023

MADRID—Attendees for the European Society for Medical Oncology Congress 2023 arrived in Madrid to torrential downpours Thursday evening, a gloomy atmosphere that did not reflect the overall excitem | ESMO attendees arrived in Madrid to torrential downpours Thursday evening, a gloomy atmosphere that did not reflect the overall excitement of an industry conference that promised to showcase breakthroughs in breast, lung and prostate cancer.

105

105

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Medicine

BioSpace

OCTOBER 22, 2023

The non-alcoholic steatohepatitis space is still a “big mystery,” analysts tell BioSpace, but its connection to weight loss could provide an additional opportunity for contenders.

Marketing 105

Marketing 105

JAMA Internal Medicine

OCTOBER 22, 2023

This cohort study assesses whether endogenous and exogenous thyrotoxicosis is associated with higher risk of cognitive disorders in adults 65 years and older.

104

104

Fierce Pharma

OCTOBER 22, 2023

Novartis has high hopes for its radiotherapy Pluvicto. | As Novartis aims to move its radiotherapy Pluvicto into an earlier treatment setting in prostate cancer, it has posted a mixed bag of trial data that cast a cloud of uncertainty over its regulatory path forward.

Trials 101

Trials 101

BioSpace

OCTOBER 22, 2023

While sensitive and specific biomarkers for Alzheimer’s disease have recently taken a leap forward, the Parkinson’s space has lagged behind. Neurofilament Light Chain could change that.

102

102

Rethinking Clinical Trials

OCTOBER 22, 2023

What Are Pragmatic Clinical Trials? Description In this video, Dr. Lesley Curtis describes pragmatic clinical trials. Speaker Lesley Curtis, PhD Professor of Population Health Sciences and Medicine, Duke University Duke Clinical Research Institute Collaboratory Steering Committee Chair Related Why Should I Do A Pragmatic Trial? The post What Are Pragmatic Clinical Trials?

Clinical Trials 100

Clinical Trials Clinical Trials Trials Clinical Research 100

BioSpace

OCTOBER 22, 2023

The label for the achondroplasia drug, which promotes endochondral bone growth, now covers children under five years of age with the rare genetic disease causing the most common form of dwarfism.

FDA Approval 96

FDA Approval Genetic Disease Genetics Drugs 96

Advertisement

Clinical Supply

Rethinking Clinical Trials

OCTOBER 22, 2023

Why Should I Do A Pragmatic Trial? Description Dr. Lesley Curtis discusses reasons to conduct pragmatic clinical trials. Speaker Lesley Curtis, PhD Professor of Population Health Sciences and Medicine, Duke University Duke Clinical Research Institute Collaboratory Steering Committee Chair Related What Are Pragmatic Clinical Trials? The post Why Should I Do A Pragmatic Trial?

Trials 100

Trials Clinical Trials Clinical Trials Clinical Research 100

BioSpace

OCTOBER 22, 2023

The competitors posted promising survival data for their respective blockbuster PD-1 inhibitors—Keytruda and Opdivo—emphasizing the potential of these therapies in bladder cancer patients.

95

95

pharmaphorum

OCTOBER 22, 2023

ESMO: Opdivo chases Keytruda in perioperative lung cancer Phil.

69

69

BioSpace

OCTOBER 22, 2023

The Swiss drugmaker gains rights to RVT-3101 in the U.S. and Japan. Telavant was formed in late 2022 by Roivant and Pfizer, which had a 25% stake in the venture and retains rights to the antibody in other countries.

Antibody 95

Antibody 95

Advertisement

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

Clinical Trials

Drug Patent Watch

OCTOBER 22, 2023

This chart shows the drugs with the most patents in Malaysia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.… The post Which pharmaceutical drugs have the most drug patents in Malaysia? appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59

Drugs 59

Roots Analysis

OCTOBER 22, 2023

RNA therapeutics are a novel class of biopharmaceuticals that harness the power of RNA molecules for the treatment and prevention of a wide range of disorders, including oncological, and genetic disorders as well as infectious diseases. These therapeutics are broadly classified into two categories, namely coding RNAs and non-coding RNAs. Coding RNAs include messenger RNA (mRNA) and short interfering RNA (siRNA), which encode proteins and silence gene expression, respectively.

RNA 40

RNA Protein Genetics Gene Expression 40

Drug Patent Watch

OCTOBER 22, 2023

Sugammadex sodium is the generic ingredient in two branded drugs marketed by Msd Sub Merck, Aspiro, Mylan, and Sandoz and, and is included in four NDAs. There is one patent… The post New tentative approval for Sandoz drug sugammadex sodium appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59

Drugs Branding Marketing 59

Pharma in Brief

OCTOBER 22, 2023

The Federal Court has upheld a decision of the Minister of Health ( Minister ) that the new owner of a biosimilar new drug submission ( NDS ) could adopt the notice of allegation ( NOA ) served by its predecessor. Consequently, the new owner was properly added as a defendant to an on-going action under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations ( Regulations ).

Regulation 52

Regulation Drugs Compliance Manufacturing 52

Advertisement

Clinical Supply

Drug Patent Watch

OCTOBER 22, 2023

Sugammadex sodium is the generic ingredient in two branded drugs marketed by Msd Sub Merck, Aspiro, Mylan, and Sandoz and, and is included in four NDAs. There is one patent… The post New tentative approval for MYLAN drug sugammadex sodium appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59

Drugs Branding Marketing 59